Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov;32(6):541-6.
doi: 10.1097/PGP.0b013e318273fd07.

HNF-1β in ovarian carcinomas with serous and clear cell change

Deborah DeLair  1 , Guangming Han, Julie A Irving, Samuel Leung, Carol A Ewanowich, Teri A Longacre, Cyril B Gilks, Robert A Soslow
Affiliations

HNF-1β in ovarian carcinomas with serous and clear cell change

Deborah DeLair et al. Int J Gynecol Pathol. 2013 Nov.

Abstract

Many ovarian tumors, including high-grade serous carcinoma (HGSC), show clear cell change. Accurate diagnosis is important, however, as ovarian clear cell carcinoma (OCCC) is known to be less responsive to traditional types of ovarian cancer chemotherapies. In a previous study, the clinical, morphologic, and immunohistochemical features of 32 ovarian carcinomas, which had been previously diagnosed as pure OCCC (n=11), pure HGSC (n=11), and mixed serous and clear cell (MSC) (n=10), were analyzed. The immunoreactivities of WT1, ER, and p53, as well as the mitotic indices and stages of presentation of the MSC, were similar to those of HGSC. It was consequently concluded that MSC represented HGSC with clear cell change. Hepatocyte nuclear factor-1β (HNF-1β) is a relatively new immunohistochemical marker that has been shown to be rather sensitive and specific for OCCC. We thus sought to evaluate this marker in this specific group of tumors. One block each of pure HGSC and pure OCCC were stained with HNF-1β. In the cases of MSC, 2 blocks were stained when the serous and clear cell components were not present on the same slide. None (0/11) of the pure HGSC showed immunoreactivity for HNF-1β, whereas all (11/11) of the pure OCCC were positive. In the cases of MSC, both the serous and clear cell components were negative for HNF-1β. HNF-1β seems to be a sensitive and specific marker for OCCC and is not expressed in HGSC with clear cell change. The pattern of immunoreactivity of HNF-1β in tumors with both serous and clear cell change supports the conclusion that MSC are HGSC with clear cells.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
(A) Pure ovarian clear cell carcinoma. (B) HNF-1β in pure ovarian clear cell carcinoma.
FIG. 2
FIG. 2
(A) Serous component of mixed serous and clear cell carcinoma. (B) HNF-1β in the serous component of mixed serous and clear cell carcinoma.
FIG. 3
FIG. 3
(A) Clear cell component of mixed serous and clear cell carcinoma. (B) HNF-1β in the clear cell component of mixed serous and clear cell carcinoma.
See this image and copyright information in PMC

References

    1. Crozier MA, Copeland LJ, Silva EG, et al. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol. 1989;35:199–203. - PubMed
    1. Kobel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29:203–11. - PubMed
    1. Pectasides D, Pectasides E, Psyrri A, et al. Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist. 2006;11:1089–94. - PubMed
    1. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584–9. - PubMed
    1. Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 2008;99:653–8. - PMC - PubMed

MeSH terms

Substances